179 related articles for article (PubMed ID: 22388755)
1. Value of Islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin.
Koo J; Mertens RB; Mirocha JM; Wang HL; Dhall D
Mod Pathol; 2012 Jun; 25(6):893-901. PubMed ID: 22388755
[TBL] [Abstract][Full Text] [Related]
2. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases.
Schmitt AM; Riniker F; Anlauf M; Schmid S; Soltermann A; Moch H; Heitz PU; Klöppel G; Komminoth P; Perren A
Am J Surg Pathol; 2008 Mar; 32(3):420-5. PubMed ID: 18300808
[TBL] [Abstract][Full Text] [Related]
3. The immunohistochemical expression of islet 1 and PAX8 by rectal neuroendocrine tumors should be taken into account in the differential diagnosis of metastatic neuroendocrine tumors of unknown primary origin.
Koo J; Zhou X; Moschiano E; De Peralta-Venturina M; Mertens RB; Dhall D
Endocr Pathol; 2013 Dec; 24(4):184-90. PubMed ID: 24037217
[TBL] [Abstract][Full Text] [Related]
4. Comparison of PAX6 and PAX8 as immunohistochemical markers for pancreatic neuroendocrine tumors.
Lai JP; Mertens RB; Mirocha J; Koo J; Venturina M; Chung F; Mendez AB; Kahn M; Dhall D
Endocr Pathol; 2015 Mar; 26(1):54-62. PubMed ID: 25433656
[TBL] [Abstract][Full Text] [Related]
5. Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours.
Mohanty SK; Tiwari A; Bhardwaj N; Chuang F; Kim E; Lugo H; Yuan X; Diffalha SA; Peralta-Venturina M; Balzer B; Dhall D
J Clin Pathol; 2021 Sep; 74(9):582-588. PubMed ID: 32934105
[TBL] [Abstract][Full Text] [Related]
6. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma.
Sangoi AR; Ohgami RS; Pai RK; Beck AH; McKenney JK; Pai RK
Mod Pathol; 2011 Mar; 24(3):412-24. PubMed ID: 20890270
[TBL] [Abstract][Full Text] [Related]
7. Value of SATB2, ISL1, and TTF1 to differentiate rectal from other gastrointestinal and lung well-differentiated neuroendocrine tumors.
Zhao LH; Chen C; Mao CY; Xiao H; Fu P; Xiao HL; Wang G
Pathol Res Pract; 2019 Jul; 215(7):152448. PubMed ID: 31133441
[TBL] [Abstract][Full Text] [Related]
8. CDX2, SATB2, GATA3, TTF1, and PAX8 Immunohistochemistry in Krukenberg Tumors.
Chiesa-Vottero A
Int J Gynecol Pathol; 2020 Mar; 39(2):170-177. PubMed ID: 32045390
[TBL] [Abstract][Full Text] [Related]
9. Cdx2 as a marker for neuroendocrine tumors of unknown primary sites.
Erickson LA; Papouchado B; Dimashkieh H; Zhang S; Nakamura N; Lloyd RV
Endocr Pathol; 2004; 15(3):247-52. PubMed ID: 15640551
[TBL] [Abstract][Full Text] [Related]
10. PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors.
Long KB; Srivastava A; Hirsch MS; Hornick JL
Am J Surg Pathol; 2010 May; 34(5):723-9. PubMed ID: 20414099
[TBL] [Abstract][Full Text] [Related]
11. An algorithmic approach utilizing CK7, TTF1, beta-catenin, CDX2, and SSTR2A can help differentiate between gastrointestinal and pulmonary neuroendocrine carcinomas.
Yu S; Hornick JL; Gonzalez RS
Virchows Arch; 2021 Sep; 479(3):481-491. PubMed ID: 33733343
[TBL] [Abstract][Full Text] [Related]
12. PAX8 is expressed in pancreatic well-differentiated neuroendocrine tumors and in extrapancreatic poorly differentiated neuroendocrine carcinomas in fine-needle aspiration biopsy specimens.
Haynes CM; Sangoi AR; Pai RK
Cancer Cytopathol; 2011 Jun; 119(3):193-201. PubMed ID: 21328566
[TBL] [Abstract][Full Text] [Related]
13. The expression of TTF1, CDX2 and ISL1 in 74 poorly differentiated neuroendocrine carcinomas.
Lee H; Fu Z; Koo BH; Sheehan CE; Young GQ; Lin J; Patil DT; Yang Z
Ann Diagn Pathol; 2018 Dec; 37():30-34. PubMed ID: 30236546
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin.
Lin X; Saad RS; Luckasevic TM; Silverman JF; Liu Y
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):407-14. PubMed ID: 18091383
[TBL] [Abstract][Full Text] [Related]
15. Islet-1 is a sensitive but not entirely specific marker for pancreatic neuroendocrine neoplasms and their metastases.
Graham RP; Shrestha B; Caron BL; Smyrk TC; Grogg KL; Lloyd RV; Zhang L
Am J Surg Pathol; 2013 Mar; 37(3):399-405. PubMed ID: 23348208
[TBL] [Abstract][Full Text] [Related]
16. NKX6-1 Is a Novel Immunohistochemical Marker for Pancreatic and Duodenal Neuroendocrine Tumors.
Tseng IC; Yeh MM; Yang CY; Jeng YM
Am J Surg Pathol; 2015 Jun; 39(6):850-7. PubMed ID: 25871618
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical Characterization of the Origins of Metastatic Well-differentiated Neuroendocrine Tumors to the Liver.
Yang Z; Klimstra DS; Hruban RH; Tang LH
Am J Surg Pathol; 2017 Jul; 41(7):915-922. PubMed ID: 28498280
[TBL] [Abstract][Full Text] [Related]
18. Comparative immunohistochemical analysis of pulmonary and thymic neuroendocrine carcinomas using PAX8 and TTF-1.
Weissferdt A; Tang X; Wistuba II; Moran CA
Mod Pathol; 2013 Dec; 26(12):1554-60. PubMed ID: 23787439
[TBL] [Abstract][Full Text] [Related]
19. Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2.
Hermann G; Konukiewitz B; Schmitt A; Perren A; Klöppel G
Virchows Arch; 2011 Aug; 459(2):147-54. PubMed ID: 21739268
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical assessment of Pax8 expression during pancreatic islet development and in human neuroendocrine tumors.
Lorenzo PI; Jimenez Moreno CM; Delgado I; Cobo-Vuilleumier N; Meier R; Gomez-Izquierdo L; Berney T; Garcia-Carbonero R; Rojas A; Gauthier BR
Histochem Cell Biol; 2011 Nov; 136(5):595-607. PubMed ID: 21932072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
